{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:31Z","timestamp":1792513051149,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40265-025-02162-4","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:47:45Z","timestamp":1742212065000},"page":"505-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-6712","authenticated-orcid":false,"given":"Germain","family":"Honvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Lengel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Alokail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Al-Daghri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-752X","authenticated-orcid":false,"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-9393","authenticated-orcid":false,"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"2162_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bmb\/lds038","volume":"105","author":"A Litwic","year":"2013","unstructured":"Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185\u201399. https:\/\/doi.org\/10.1093\/bmb\/lds038. (Epub 2013\/01\/23. PubMed PMID: 23337796; PubMed Central PMCID: PMCPMC3690438).","journal-title":"Br Med Bull"},{"issue":"3","key":"2162_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090633","volume":"9","author":"C Palazzo","year":"2014","unstructured":"Palazzo C, Ravaud JF, Papelard A, Ravaud P, Poiraudeau S. The burden of musculoskeletal conditions. PLoS ONE. 2014;9(3): e90633. https:\/\/doi.org\/10.1371\/journal.pone.0090633. (Epub 2014\/03\/07. PubMed PMID: 24595187; PubMed Central PMCID: PMCPMC3942474).","journal-title":"PLoS ONE"},{"issue":"7","key":"2162_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/annrheumdis-2013-204763","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204763. (Epub 2014\/02\/21. PubMed PMID: 24553908).","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2162_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/1573397113666170829155149","volume":"14","author":"W Hermann","year":"2018","unstructured":"Hermann W, Lambova S, Muller-Ladner U. Current treatment options for osteoarthritis. Curr Rheumatol Rev. 2018;14(2):108\u201316. https:\/\/doi.org\/10.2174\/1573397113666170829155149.","journal-title":"Curr Rheumatol Rev"},{"issue":"Suppl 1","key":"2162_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40266-019-00661-0","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, Leclercq V, Geerinck A, Thomas T, Veronese N, Charles A, et al. Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):45\u201364. https:\/\/doi.org\/10.1007\/s40266-019-00661-0. (Epub 2019\/05\/11. PubMed PMID: 31073923; PubMed Central PMCID: PMCPMC6509095).","journal-title":"Drugs Aging"},{"key":"2162_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40266-019-00662-z","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Charles A, et al. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36:65\u201399. https:\/\/doi.org\/10.1007\/s40266-019-00662-z. (Epub 2019\/05\/11. PubMed PMID: 31073924; PubMed Central PMCID: PMCPMC6509099).","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"2162_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40266-019-00657-w","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, Reginster JY, Rannou F, Rygaert X, Geerinck A, Rabenda V, et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):101\u201327. https:\/\/doi.org\/10.1007\/s40266-019-00657-w. (Epub 2019\/05\/11. PubMed PMID: 31073925).","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"2162_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40266-019-00664-x","volume":"36","author":"E Curtis","year":"2019","unstructured":"Curtis E, Fuggle N, Shaw S, Spooner L, Ntani G, Parsons C, et al. Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):25\u201344. https:\/\/doi.org\/10.1007\/s40266-019-00664-x. (Epub 2019\/05\/11. PubMed PMID: 31073922; PubMed Central PMCID: PMCPMC6509094).","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"2162_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40266-019-00666-9","volume":"36","author":"N Fuggle","year":"2019","unstructured":"Fuggle N, Curtis E, Shaw S, Spooner L, Bruyere O, Ntani G, et al. Safety of opioids in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):129\u201343. https:\/\/doi.org\/10.1007\/s40266-019-00666-9. (Epub 2019\/05\/11. PubMed PMID: 31073926; PubMed Central PMCID: PMCPMC6509215).","journal-title":"Drugs Aging"},{"issue":"9","key":"2162_CR10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/0091270007304776","volume":"47","author":"SP Glasser","year":"2007","unstructured":"Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol. 2007;47(9):1074\u201386. https:\/\/doi.org\/10.1177\/0091270007304776. (Epub 2007\/09\/04. PubMed PMID: 17766697).","journal-title":"J Clin Pharmacol"},{"key":"2162_CR11","unstructured":"WHO. The Importance of Pharmacovigilance - Safety Monitoring of Medicinal Products: World Health Organization; 2002. Available from: http:\/\/apps.who.int\/medicinedocs\/fr\/d\/Js4893e\/. Accessed 01 Mar 2022."},{"key":"2162_CR12","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). Available from: www.handbook.cochrane.org The Cochrane Collaboration; 2011 Updated March 2011. Accessed 15 July 2019."},{"issue":"10","key":"2162_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.005. (Epub 2009\/07\/23. PubMed PMID: 19631508).","journal-title":"J Clin Epidemiol"},{"key":"2162_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/bmj.39024.487720.68","volume":"334","author":"HM Krumholz","year":"2007","unstructured":"Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ. 2007;334:120\u20133. https:\/\/doi.org\/10.1136\/bmj.39024.487720.68.","journal-title":"BMJ"},{"key":"2162_CR15","doi-asserted-by":"crossref","unstructured":"Thomas D, Klika C. Pharmacovigilance systems. Clinical Pharmacy Education, Practice and Research2019. p. 215-25.","DOI":"10.1016\/B978-0-12-814276-9.00015-5"},{"issue":"1","key":"2162_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","volume":"7","author":"LL Ma","year":"2020","unstructured":"Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7. https:\/\/doi.org\/10.1186\/s40779-020-00238-8. (Epub 2020\/03\/01. PubMed PMID: 32111253; PubMed Central PMCID: PMCPMC7049186).","journal-title":"Mil Med Res"},{"issue":"2","key":"2162_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/jebm.12427","volume":"14","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Huang L, Wang D, Ren P, Hong Q, Kang D. The ROBINS-I and the NOS had similar reliability but differed in applicability: A random sampling observational studies of systematic reviews\/meta-analysis. J Evid Based Med. 2021;14(2):112\u201322. https:\/\/doi.org\/10.1111\/jebm.12427. (Epub 2021\/05\/19. PubMed PMID: 34002466).","journal-title":"J Evid Based Med"},{"key":"2162_CR18","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis: JBI; 2020. Available from: https:\/\/synthesismanual.jbi.global. Accessed 26 June 2024.","DOI":"10.46658\/JBIRM-17-06"},{"key":"2162_CR19","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). Available from: www.handbook.cochrane.org: The Cochrane Collaboration; 2011 Updated March 2011."},{"issue":"6","key":"2162_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/pds.1590","volume":"17","author":"M Cunnington","year":"2008","unstructured":"Cunnington M, Webb D, Qizilbash N, Blum D, Mander A, Jonsson Funk M, et al. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf. 2008;17(6):601\u20138. https:\/\/doi.org\/10.1002\/pds.1590.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2162_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2009.03588.x","volume":"69","author":"D Laharie","year":"2010","unstructured":"Laharie D, Droz-Perroteau C, Benichou J, Amouretti M, Blin P, Begaud B, et al. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol. 2010;69(3):295\u2013302. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03588.x. (Epub 2010\/03\/18. PubMed PMID: 20233201; PubMed Central PMCID: PMCPMC2829700).","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2162_CR22","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keg401","volume":"42","author":"D Layton","year":"2003","unstructured":"Layton D, Hughes K, Harris S, Shakir SAW. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford). 2003;42(11):1354\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2162_CR23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/rheumatology\/keg376","volume":"42","author":"D Layton","year":"2003","unstructured":"Layton D, Hughes K, Harris S, Shakir SAW. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford). 2003;42(11):1332\u201341.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2162_CR24","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.amjmed.2017.06.028","volume":"130","author":"DH Solomon","year":"2017","unstructured":"Solomon DH, Husni ME, Libby PA, Yeomans ND, Lincoff AM, Lupsilonscher TF, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415\u201322. https:\/\/doi.org\/10.1016\/j.amjmed.2017.06.028. (PubMed PMID: 28756267).","journal-title":"Am J Med"},{"issue":"4","key":"2162_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/art.40400","volume":"70","author":"DH Solomon","year":"2018","unstructured":"Solomon DH, Husni ME, Wolski KE, Wisniewski LM, Borer JS, Graham DY, et al. Differences in safety of nonsteroidal antiinflammatory drugs in patients with osteoarthritis and patients with rheumatoid arthritis: a randomized clinical trial. Arthritis Rheumatol. 2018;70(4):537\u201346. https:\/\/doi.org\/10.1002\/art.40400. (Epub 2017\/12\/22. PubMed PMID: 29266879).","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"2162_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/pds.3617","volume":"23","author":"FJ de Abajo","year":"2014","unstructured":"de Abajo FJ, Gil MJ, Garcia Poza P, Bryant V, Oliva B, Timoner J, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23(11):1128\u201338. https:\/\/doi.org\/10.1002\/pds.3617. (Epub 2014\/04\/03. PubMed PMID: 24692325).","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2162_CR27","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2019-0338","author":"J Khotib","year":"2019","unstructured":"Khotib J, Setiawan HU, Nurhan AD, Rahadiansyah E, Ardianto C, Rahmadi M. Analysis of effectiveness and drug related problems of pain reliever for knee osteoarthritis: Weighing clinical risk and benefit. J Basic Clin Physiol Pharmacol. 2019. https:\/\/doi.org\/10.1515\/jbcpp-2019-0338.","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"11","key":"2162_CR28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/rheumatology\/keg379","volume":"42","author":"D Layton","year":"2003","unstructured":"Layton D, Heeley E, Hughes K, Shakir SAW. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford). 2003;42(11):1342\u201353.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2162_CR29","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/rheumatology\/keg141","volume":"42","author":"D Layton","year":"2003","unstructured":"Layton D, Heeley E, Hughes K, Shakir SAW. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed refocoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology. 2003;42(5):622\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/keg141.","journal-title":"Rheumatology"},{"issue":"4","key":"2162_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4103\/epj.epj_69_22","volume":"21","author":"AM Varghese","year":"2022","unstructured":"Varghese AM, Kandra NV, Vangoori Y, Uppala PK, Uttaravelli U, Saibaba SV, et al. Theophylline and meloxicam-induced Stevens-Johnson syndrome (SJS): rare case reports. Egypt Pharm J. 2022;21(4):531\u20135. https:\/\/doi.org\/10.4103\/epj.epj_69_22.","journal-title":"Egypt Pharm J"},{"issue":"ec2, 7600076","key":"2162_CR31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2165\/00003495-199300461-00068","volume":"46 Suppl 1","author":"RL Dreiser","year":"1993","unstructured":"Dreiser RL, Benevelli DC. Long term tolerability profile of nimesulide in the treatment of osteoarthritis. Drugs. 1993;46 Suppl 1(ec2, 7600076):270\u20134.","journal-title":"Drugs"},{"issue":"3","key":"2162_CR32","first-page":"197","volume":"17","author":"MG Pochobradsky","year":"1991","unstructured":"Pochobradsky MG, Mele G, Beretta A, Montagnani G. Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. Drugs Exp Clin Res. 1991;17(3):197\u2013204.","journal-title":"Drugs Exp Clin Res"},{"issue":"1","key":"2162_CR33","first-page":"7","volume":"14","author":"M Busson","year":"1986","unstructured":"Busson M. A long-term study of flurbiprofen in rheumatological disorders: II. Osteoarthrosis. J Int Med Res. 1986;14(1):7\u201312.","journal-title":"J Int Med Res"},{"issue":"6","key":"2162_CR34","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s10157-017-1406-9","volume":"21","author":"N Otsuka","year":"2017","unstructured":"Otsuka N, Yataba I, Matsushita I, Matsumoto H, Hoshino Y, Terada Y. A minimal impact of long-term S-flurbiprofen plaster application on kidney function in osteoarthritis patients. Clin Exp Nephrol. 2017;21(6):1060\u20137. https:\/\/doi.org\/10.1007\/s10157-017-1406-9.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"2162_CR35","first-page":"113","volume":"4","author":"A Emanueli","year":"1981","unstructured":"Emanueli A, Sacchetti G. Indoprofen in the treatment of osteoarthritis. Results of a phase IV multiclinic study in 1629 patients. Eur J Rheumatol Inflamm. 1981;4(1):113\u20137.","journal-title":"Eur J Rheumatol Inflamm"},{"issue":"6","key":"2162_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/875512259701300610","volume":"13","author":"ME Ernst","year":"1997","unstructured":"Ernst ME, Buys LM. Reevaluating the safety of concurrent warfarin and ibuprofen therapy: a case report. J Pharm Technol. 1997;13(6):244\u20137. https:\/\/doi.org\/10.1177\/875512259701300610.","journal-title":"J Pharm Technol"},{"issue":"6","key":"2162_CR37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/030006058000800601","volume":"8","author":"AJ Gordon","year":"1980","unstructured":"Gordon AJ, Estabrooks TF, Dessain P. Treatment of osteoarthrosis with piroxicam in general practice: long-term follow-up in a multicentre study. J Int Med Res. 1980;8(6):375\u201381.","journal-title":"J Int Med Res"},{"issue":"2","key":"2162_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4103\/0253-7613.153436","volume":"47","author":"JS Kameshwari","year":"2015","unstructured":"Kameshwari JS, Devde R. A case report on toxic epidermal necrolysis with etoricoxib. Indian J Pharmacol. 2015;47(2):221\u20133. https:\/\/doi.org\/10.4103\/0253-7613.153436. (Epub 2015\/04\/17. PubMed PMID: 25878388; PubMed Central PMCID: PMCPMC4386137).","journal-title":"Indian J Pharmacol."},{"issue":"7\u20138","key":"2162_CR39","first-page":"379","volume":"55","author":"D Maestracci","year":"1979","unstructured":"Maestracci D, Sarre J. Long-term therapy of osteoarthritis of the hip and the knee by sulindac (a cooperative trial in general practice). Semaine des Hopitaux. 1979;55(7\u20138):379\u201383.","journal-title":"Semaine des Hopitaux."},{"issue":"5","key":"2162_CR40","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1185\/03007991003694522","volume":"26","author":"Pillai L, Burnett BP, Levy RM, Group GSC","year":"2010","unstructured":"Pillai L, Burnett BP, Levy RM, Group GSC. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Curr Med Res Opin. 2010;26(5):1055\u201363. https:\/\/doi.org\/10.1185\/03007991003694522.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2162_CR41","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/hep.1840220320","volume":"22","author":"AT Banks","year":"1995","unstructured":"Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatology. 1995;22(3):820\u20137. https:\/\/doi.org\/10.1002\/hep.1840220320.","journal-title":"Hepatology"},{"issue":"1","key":"2162_CR42","doi-asserted-by":"publisher","first-page":"129.e1-e2","DOI":"10.1016\/j.ajem.2008.04.014","volume":"27","author":"NS Salemis","year":"2009","unstructured":"Salemis NS. Spontaneous thigh hematoma associated with diclofenac. Am J Emerg Med. 2009;27(1):129.e1-e2. https:\/\/doi.org\/10.1016\/j.ajem.2008.04.014.","journal-title":"Am J Emerg Med"},{"issue":"2","key":"2162_CR43","first-page":"229","volume":"10","author":"I Scaricabarozzi","year":"1988","unstructured":"Scaricabarozzi I, Chinea B, Scotti A. Imidazole salicylate in the treatment of osteoarthrosis and musculoskeletal trauma: a postmarketing survey. Clin Ther. 1988;10(2):229\u201336.","journal-title":"Clin Ther"},{"issue":"1 Supplement","key":"2162_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02274752","volume":"10","author":"U Serni","year":"1990","unstructured":"Serni U. Global safety of etodolac: reports from worldwide postmarketing surveillance studies. Rheumatol Int. 1990;10(1 Supplement):23\u20137. https:\/\/doi.org\/10.1007\/BF02274752.","journal-title":"Rheumatol Int"},{"issue":"1","key":"2162_CR45","first-page":"25","volume":"2","author":"M Thompson","year":"1979","unstructured":"Thompson M, Akyol MS, Cosh J. Naproxen in patients with osteoarthritis and intolerance to other non-steroidal anti-inflammatory drugs. Eur J Rheumatol Inflamm. 1979;2(1):25\u20138.","journal-title":"Eur J Rheumatol Inflamm"},{"issue":"Suppl. 1","key":"2162_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000137782","volume":"25","author":"E Urdaneta","year":"1982","unstructured":"Urdaneta E, Bonnelli J, Curiel HE, Soria G. Long-term clinical evaluation of fenbufen in the treatment of rheumatoid arthritis and osteoarthritis: Latin-American experience. Pharmacology. 1982;25(Suppl. 1):79\u201387. https:\/\/doi.org\/10.1159\/000137782.","journal-title":"Pharmacology"},{"issue":"3","key":"2162_CR47","first-page":"128","volume":"34","author":"C Day","year":"2021","unstructured":"Day C, Peter J. The many faces of NSAID reactions. Curr Allergy Clin Immunol. 2021;34(3):128\u201331.","journal-title":"Curr Allergy Clin Immunol"},{"key":"2162_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.curtheres.2018.04.001","volume":"88","author":"D Baron","year":"2018","unstructured":"Baron D, Flin C, Porterie J, Despaux J, Vincent P. Hyaluronic Acid Single Intra-Articular Injection in Knee Osteoarthritis: A Multicenter Open Prospective Study (ART-ONE 75) with placebo post hoc comparison. Curr Ther Res Clin Exp. 2018;88:35\u201346. https:\/\/doi.org\/10.1016\/j.curtheres.2018.04.001. (Epub 2018\/08\/03. PubMed PMID: 30069277; PubMed Central PMCID: PMCPMC6066596).","journal-title":"Curr Ther Res Clin Exp"},{"key":"2162_CR49","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2147\/DDDT.S81524","volume":"9","author":"K Bashaireh","year":"2015","unstructured":"Bashaireh K, Naser Z, Hawadya KA, Sorour S, Al-Khateeb RN. Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study. Drug Des Devel Ther. 2015;9:2063\u201372. https:\/\/doi.org\/10.2147\/DDDT.S81524. (Epub 2015\/04\/22. PubMed PMID: 25897212; PubMed Central PMCID: PMCPMC4396588).","journal-title":"Drug Des Devel Ther."},{"issue":"3","key":"2162_CR50","first-page":"407","volume":"47","author":"C Foti","year":"2011","unstructured":"Foti C, Cisari C, Carda S, Giordan N, Rocco A, Frizziero A, et al. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate in synovial joints with osteoarthritis. Eur J Phys Rehabil Med. 2011;47(3):407\u201315.","journal-title":"Eur J Phys Rehabil Med"},{"issue":"6","key":"2162_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287222","volume":"18","author":"JG Kim","year":"2023","unstructured":"Kim JG, Kim K-I, Park K-B, Park Y-G, Bae JH, Seo Y-J, et al. Safety and effectiveness of intra-articular injection of a highly cross-linked hyaluronic acid, LBSA0103 (Synovian): Results from a post-marketing surveillance study in South Korea. PLoS ONE. 2023;18(6):e0287222. https:\/\/doi.org\/10.1371\/journal.pone.0287222.","journal-title":"PLoS ONE"},{"issue":"1","key":"2162_CR52","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12891-021-04672-0","volume":"22","author":"DM Long","year":"2021","unstructured":"Long DM, Fitzpatrick J. Safety and efficacy of a single intra-articular injection of hyaluronic acid in osteoarthritis of the hip: a case series of 87 patients. BMC Musculoskelet Disord. 2021;22(1):797. https:\/\/doi.org\/10.1186\/s12891-021-04672-0.","journal-title":"BMC Musculoskelet Disord"},{"issue":"101591806","key":"2162_CR53","doi-asserted-by":"publisher","first-page":"1518401","DOI":"10.1155\/2017\/1518401","volume":"2017","author":"F Manfreda","year":"2017","unstructured":"Manfreda F, Rinonapoli G, Nardi A, Antinolfi P, Caraffa A. A fatal sepsis caused by hyaluronate knee injection: how much the medical history and the informed consent might be important? Case Rep Orthop. 2017;2017(101591806):1518401. https:\/\/doi.org\/10.1155\/2017\/1518401.","journal-title":"Case Rep Orthop"},{"issue":"8","key":"2162_CR54","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s10067-022-06154-7","volume":"41","author":"MC Micu","year":"2022","unstructured":"Micu MC, Micu A, Bolboaca SD. Ultrasound-guided injection with hyaluronic acid in hip osteoarthritis: efficacy and safety in a real-life setting. Clin Rheumatol. 2022;41(8):2491\u20138. https:\/\/doi.org\/10.1007\/s10067-022-06154-7.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"2162_CR55","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00402-011-1353-y","volume":"131","author":"A Migliore","year":"2011","unstructured":"Migliore A, Massafra U, Bizzi E, Lagana B, Germano V, Piscitelli P, et al. Intra-articular injection of hyaluronic acid (MW 1500\u20132000 kDa; HyalOne) in symptomatic osteoarthritis of the hip: a prospective cohort study. Arch Orthop Trauma Surg. 2011;131(12):1677\u201385. https:\/\/doi.org\/10.1007\/s00402-011-1353-y. (Epub 2011\/08\/05. PubMed PMID: 21814776).","journal-title":"Arch Orthop Trauma Surg"},{"issue":"1","key":"2162_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1721727X1201000108","volume":"10","author":"A Migliore","year":"2012","unstructured":"Migliore A, Massafra U, Bizzi E, Giovannangeli F, Tormenta S. Intraarticular ultrasound-guided injection of sinovial\u00ae forte 1.6% in patients affected by symptomatic hip osteoarthritis: Effectiveness and safety in a large cohort of patients. Eur J Inflamm. 2012;10(1):71\u20139. https:\/\/doi.org\/10.1177\/1721727X1201000108.","journal-title":"Eur J Inflamm"},{"issue":"7","key":"2162_CR57","first-page":"1635","volume":"21","author":"A Migliore","year":"2017","unstructured":"Migliore A, Massafra U, Frediani B, Bizzi E, Sinelnikov Yzchaki E, Gigliucci G, et al. HyalOne R in the treatment of symptomatic hip OA - data from the ANTIAGE register: seven years of observation. Eur Rev Med Pharmacol Sci. 2017;21(7):1635\u201344.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"2162_CR58","first-page":"1433","volume":"32","author":"A Migliore","year":"2018","unstructured":"Migliore A, Frediani B, Gigliucci G, Anichini SE, Cassol M, Crimaldi S, et al. One-year follow-up showing effects of single intra-articular injection of hyaluronic acid (1,500\u20132,000 kDa) in symptomatic knee osteoarthritis. J Biol Regul Homeost Agents. 2018;32(6):1433\u201341.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"101531415","key":"2162_CR59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/ORR.S239355","volume":"12","author":"A Migliore","year":"2020","unstructured":"Migliore A, Frediani B, Gigliucci G, Foti C, Crimaldi S, De Lucia O, et al. Efficacy of a Single intra-articular HYMOVIS ONE injection for managing symptomatic hip osteoarthritis: a 12-month follow-up retrospective analysis of the ANTIAGE register data. Orthop Res Rev. 2020;12(101531415):19\u201326. https:\/\/doi.org\/10.2147\/ORR.S239355.","journal-title":"Orthop Res Rev"},{"issue":"3","key":"2162_CR60","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.23812\/21-178-L","volume":"35","author":"A Migliore","year":"2021","unstructured":"Migliore A, Graziano E, Martin LSM, Sorbino A, Raichi M, Boni G. Three-year management of hip osteoarthritis with intra-articular polynucleotides: a real-life cohort retrospective study. J Biol Regul Homeost Agents. 2021;35(3):1189\u201394. https:\/\/doi.org\/10.23812\/21-178-L.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"3","key":"2162_CR61","first-page":"307","volume":"21","author":"DH Neustadt","year":"2003","unstructured":"Neustadt DH. Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol. 2003;21(3):307\u201311.","journal-title":"Clin Exp Rheumatol"},{"issue":"101480507","key":"2162_CR62","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/1874312901408010054","volume":"8","author":"S Pal","year":"2014","unstructured":"Pal S, Thuppal S, Reddy KJ, Avasthi S, Aggarwal A, Bansal H, et al. Long-term (1-year) safety and efficacy of a single 6-ml injection of Hylan g-f 20 in Indian patients with symptomatic knee osteoarthritis. Open Rheumatol J. 2014;8(101480507):54\u201368. https:\/\/doi.org\/10.2174\/1874312901408010054.","journal-title":"Open Rheumatol J"},{"issue":"4","key":"2162_CR63","doi-asserted-by":"publisher","first-page":"327","DOI":"10.12809\/hkmj144329","volume":"21","author":"CH Yan","year":"2015","unstructured":"Yan CH, Chan WL, Yuen WH, Yung PSH, Ip KY, Fan JCH, et al. Efficacy and safety of hylan G-F 20 injection in treatment of knee osteoarthritis in Chinese patients: results of a prospective, multicentre, longitudinal study. Hong Kong Med J Xianggang yi xue za zhi. 2015;21(4):327\u201332. https:\/\/doi.org\/10.12809\/hkmj144329.","journal-title":"Hong Kong Med J Xianggang yi xue za zhi."},{"issue":"5","key":"2162_CR64","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5114\/reum.2016.63661","volume":"54","author":"P Gluszko","year":"2016","unstructured":"Gluszko P, Stasiek M. Symptom-modifying effects of oral avocado\/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016;54(5):217\u201326. https:\/\/doi.org\/10.5114\/reum.2016.63661. (Epub 2016\/12\/21. PubMed PMID: 27994265; PubMed Central PMCID: PMCPMC5149568).","journal-title":"Reumatologia"},{"key":"2162_CR65","unstructured":"Renapurkar DK, Mathur S, Jagdishwer Rao KL. Evaluation of efficacy and safety of diacerein in osteoarthritis of knee joint. Int J Pharma Bio Sci. 2010;1(3):1\u201312."},{"issue":"1","key":"2162_CR66","first-page":"54","volume":"106","author":"A Sharma","year":"2008","unstructured":"Sharma A, Rathod R, Baliga VP. An open prospective study on postmarketing evaluation of the efficacy and tolerability of diacerein in osteo-arthritis of the knee (DOK). J Indian Med Assoc. 2008;106(1):54\u201368 (Epub 2008\/08\/19. PubMed PMID: 18705272; PubMed Central PMCID: PMCPMID: 18705272).","journal-title":"J Indian Med Assoc"},{"issue":"3","key":"2162_CR67","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36310","volume":"15","author":"EC-P Chu","year":"2023","unstructured":"Chu EC-P, Huang KHK, Cheung G, Ng G, Lin A. Delayed skin allergy to glucosamine chondroitin supplement. Cureus. 2023;15(3): e36310. https:\/\/doi.org\/10.7759\/cureus.36310.","journal-title":"Cureus."},{"issue":"1134","key":"2162_CR68","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/postgradmedj-2019-136957","volume":"96","author":"C Hoban","year":"2020","unstructured":"Hoban C, Byard R, Musgrave I. Hypersensitive adverse drug reactions to glucosamine and chondroitin preparations in Australia between 2000 and 2011. Postgrad Med J. 2020;96(1134):190\u20133. https:\/\/doi.org\/10.1136\/postgradmedj-2019-136957. (Epub 2019\/10\/11. PubMed PMID: 31597786).","journal-title":"Postgrad Med J"},{"issue":"6","key":"2162_CR69","doi-asserted-by":"publisher","first-page":"443","DOI":"10.5312\/wjo.v14.i6.443","volume":"14","author":"AM Lila","year":"2023","unstructured":"Lila AM, Alekseeva LI, Baranov AA, Taskina EA, Kashevarova NG, Lapkina NA, et al. Chondroitin sulfate and glucosamine combination in patients with knee and hip osteoarthritis: a long-term observational study in Russia. World J Orthop. 2023;14(6):443\u201357. https:\/\/doi.org\/10.5312\/wjo.v14.i6.443.","journal-title":"World J Orthop"},{"issue":"2","key":"2162_CR70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1148\/radiol.210668","volume":"304","author":"DN Graf","year":"2022","unstructured":"Graf DN, Thallinger A, Zubler V, Sutter R. Intraarticular steroid injection in hip and knee with fluoroscopic guidance: reassessing safety. Radiology. 2022;304(2):363\u20139. https:\/\/doi.org\/10.1148\/radiol.210668.","journal-title":"Radiology"},{"issue":"8","key":"2162_CR71","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/art.42118","volume":"74","author":"A Latourte","year":"2022","unstructured":"Latourte A, Rat A-C, Omorou A, Ngueyon-Sime W, Eymard F, Sellam J, et al. Do glucocorticoid injections increase the risk of knee osteoarthritis progression over 5 years? Arthritis Rheumatol (Hoboken, NJ). 2022;74(8):1343\u201351. https:\/\/doi.org\/10.1002\/art.42118.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)."},{"issue":"804","key":"2162_CR72","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.53738\/REVMED.2022.18.804.2181","volume":"18","author":"S Perolini","year":"2022","unstructured":"Perolini S, Paschoud C, Venkatachalam A. Complication of an intra-articular injection with corticosteroids. Revue Medicale Suisse. 2022;18(804):2181\u20133. https:\/\/doi.org\/10.53738\/REVMED.2022.18.804.2181.","journal-title":"Revue Medicale Suisse."},{"issue":"3","key":"2162_CR73","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1249\/JSR.0000000000000259","volume":"15","author":"DM Smuin","year":"2016","unstructured":"Smuin DM, Seidenberg PH, Sirlin EA, Phillips SF, Silvis ML. Rare adverse events associated with corticosteroid injections: a case series and literature review. Curr Sports Med Rep. 2016;15(3):171\u20136. https:\/\/doi.org\/10.1249\/JSR.0000000000000259.","journal-title":"Curr Sports Med Rep"},{"issue":"1","key":"2162_CR74","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/15360288.2022.2051676","volume":"36","author":"L Meyer-Junco","year":"2022","unstructured":"Meyer-Junco L, Rea B, Mendoza K, Fudin J. Application site reactions from the buprenorphine transdermal patch: a case series. J Pain Palliat Care Pharmacother. 2022;36(1):49\u201354. https:\/\/doi.org\/10.1080\/15360288.2022.2051676.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"2162_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/00325481.2017.1274224","volume":"129","author":"L Taber","year":"2017","unstructured":"Taber L, Baldridge S, He E, Ripa SR. Hysingla\u00ae ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis. Postgrad Med. 2017;129(1):133\u20139. https:\/\/doi.org\/10.1080\/00325481.2017.1274224.","journal-title":"Postgrad Med"},{"key":"2162_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040580","author":"TY Wu","year":"2023","unstructured":"Wu TY, Wu WT, Lee RP, Chen IH, Yu TC, Wang JH, et al. Tramadol may increase risk of hip fracture in older adults with post-traumatic osteoarthritis. J Perso Med. 2023. https:\/\/doi.org\/10.3390\/jpm13040580.","journal-title":"J Perso Med"},{"issue":"5A","key":"2162_CR77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0002-9343(87)90858-8","volume":"83","author":"R Berger","year":"1987","unstructured":"Berger R, Nowak H. A new medical approach to the treatment of osteoarthritis. Report of an open phase IV study with ademetionine (Gumbaral). Am J Med. 1987;83(5A):84\u20138.","journal-title":"Am J Med"},{"issue":"7903310, k8t","key":"2162_CR78","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jep.2016.05.031","volume":"189","author":"C-W Ha","year":"2016","unstructured":"Ha C-W, Park Y-B, Kyung H-S, Han C-S, Bae K-C, Lim H-C, et al. Gastrointestinal safety and efficacy of long-term GCSB-5 use in patients with osteoarthritis: A 24-week, multicenter study. J Ethnopharmacol. 2016;189(7903310, k8t):310\u20138. https:\/\/doi.org\/10.1016\/j.jep.2016.05.031.","journal-title":"J Ethnopharmacol"},{"key":"2162_CR79","unstructured":"!!! INVALID CITATION !!! [27]."},{"issue":"26","key":"2162_CR80","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Yeomans ND, Solomon DH, Luscher TF, Libby P, Husni ME, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1611593. (Epub 2016\/12\/14. PubMed PMID: 27959716).","journal-title":"N Engl J Med"},{"key":"2162_CR81","doi-asserted-by":"publisher","unstructured":"da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021;375:n2321. Epub 2021\/10\/14. https:\/\/doi.org\/10.1136\/bmj.n2321. PubMed PMID: 34642179; PubMed Central PMCID: PMCPMC8506236 at www.icmje.org\/disclosure-of-interest\/ and declare: support from the Arthritis Society, Canada Research Chairs Programme, National Institute for Health Research, Chevening Scholarship Program for the submitted work. P.J. serves as unpaid member of the steering group of trials funded by Appili Therapeutics, Abbot Vascular, and Terumo; he has received research grants to the institution from Appili Therapeutics, and honorariums to the institution for participation in advisory boards or consulting from Amgen, Ava and Fresenius, but has not received personal payments by any pharmaceutical company or device manufacturer. A.J.S. has been a paid consultant by Janssen-Cilag and GlaxoSmithKline. P.T. has received royalty payments as contributing author and editor for journals, textbooks and articles published by Elsevier, Little Brown, Wolters Kluwer, and John Wiley and Sons; PT has been an independent paid consultant to CHEOR Solutions (Canada), Innovative Science Solutions LLC and Reformulary Group; he serves as unpaid chair of the management subcommittee, of the executive committee of OMERACT; OMERACT receives unrestricted educational grants from the American College of Rheumatology, European League of Rheumatology, Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech\/Roche, Genzyme\/Sanofi, Horizon Pharma, Merck, Novartis, Pfizer, PPD, Quintiles, Regeneron, Savient, Takeda Pharmaceutical, UCB Group, Vertex, Forest and Bioiberica; P.T. serves as an independent committee member in Data Safety Monitoring Boards of FDA approved trials being conducted by UCB Biopharma GmbH and SPRL, Parexel International and Prahealth Sciences. All other authors report no financial relationships with any organizations that might have an interest in the submitted work in the previous three years. All authors report no other relationships or activities that could appear to have influenced the submitted work.","DOI":"10.1136\/bmj.n2321"},{"issue":"2","key":"2162_CR82","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317. https:\/\/doi.org\/10.2165\/00002018-199920020-00002. (Epub 1999\/03\/19. PubMed PMID: 10082069).","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"2162_CR83","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40266-019-00667-8","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, Bannuru RR, Bruyere O, Rannou F, Herrero-Beaumont G, Uebelhart D, et al. Recommendations for the reporting of harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs Aging. 2019;36(Suppl 1):145\u201359. https:\/\/doi.org\/10.1007\/s40266-019-00667-8. (Epub 2019\/05\/11. PubMed PMID: 31073927; PubMed Central PMCID: PMCPMC6509216).","journal-title":"Drugs Aging"},{"issue":"3","key":"2162_CR84","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.semarthrit.2019.04.008","volume":"49","author":"O Bruy\u00e8re","year":"2019","unstructured":"Bruy\u00e8re O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337\u201350. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.04.008. (Epub 2019\/05\/28. PubMed PMID: 31126594).","journal-title":"Semin Arthritis Rheum"},{"key":"2162_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ostima.2023.100157","author":"HA Ibad","year":"2023","unstructured":"Ibad HA, Kasaeian A, Ghotbi E, Roemer F, Jarraya M, Ghazi-Sherbaf F, et al. Longitudinal MRI-defined cartilage loss and radiographic joint space narrowing following intra-articular corticosteroid injection for knee osteoarthritis: a systematic review and meta-analysis. Osteoarthr Imaging. 2023. https:\/\/doi.org\/10.1016\/j.ostima.2023.100157. (Epub 2024\/03\/08. PubMed PMID: 38455990; PubMed Central PMCID: PMCPMC10919225).","journal-title":"Osteoarthr Imaging."},{"issue":"11","key":"2162_CR86","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","volume":"27","author":"RR Bannuru","year":"2019","unstructured":"Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578\u201389. https:\/\/doi.org\/10.1016\/j.joca.2019.06.011. (Epub 2019\/07\/07. PubMed PMID: 31278997).","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"2162_CR87","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/art.41142","volume":"72","author":"SL Kolasinski","year":"2020","unstructured":"Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220\u201333. https:\/\/doi.org\/10.1002\/art.41142.","journal-title":"Arthritis Rheumatol"},{"key":"2162_CR88","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jclinepi.2021.04.012","volume":"137","author":"AI Dobrescu","year":"2021","unstructured":"Dobrescu AI, Nussbaumer-Streit B, Klerings I, Wagner G, Persad E, Sommer I, et al. Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review. J Clin Epidemiol. 2021;137:209\u201317. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.04.012. (Epub 2021\/05\/03. PubMed PMID: 33933579).","journal-title":"J Clin Epidemiol"},{"key":"2162_CR89","doi-asserted-by":"publisher","unstructured":"Spelsberg A, Prugger C, Doshi P, Ostrowski K, Witte T, Husgen D, et al. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ. 2017;356:j337. Epub 2017\/02\/09. https:\/\/doi.org\/10.1136\/bmj.j337. PubMed PMID: 28174182; PubMed Central PMCID: PMCPMC5477378 at www.icmje.org\/coi_disclosure.pdf and declare: no support from any organisation for the submitted work other than Transparency International Germany; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. PD is an unpaid member of the IMEDS steering committee at the Reagan-Udall Foundation for the FDA, which focuses on drug safety research. PD is also an associate editor at The BMJ.","DOI":"10.1136\/bmj.j337"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02162-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:53:08Z","timestamp":1743303188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02162-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2162"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02162-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Distinguished Scientist Fellowship Program (DSFP) of the King Saud University (Riyadh, Kingdom of Saudi Arabia), and by an Unrestricted Educational Grant provided by Interface Science et Recherche ASBL, a Belgian non-for-profit organization aiming at supporting high-quality scientific research conducted at the University of Li\u00e8ge (Belgium). The authors of this research are grateful to ReumaNL and to Doctor Corn\u00e9 Baatenburg de Jong for their support to their scientific activities. However, the conception of the study and development of the protocol, the collection and synthesis of the data and their interpretation, the drafting of this manuscript and the decision to submit it for publication were the sole responsibility of the authors, without any influence of any third party.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"G. Honvo, L. Lengel\u00e9, M.\u00a0Alokail, and\u00a0N.\u00a0Al\u2011Daghri\u00a0have nothing to declare. O. Bruy\u00e8re reports consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris, outside the submitted work. J.Y.R. (1) has received consultancy fees from IBSA, Promedius, Viatris, Rejuvenate Biomed, Celltrion, Agnovos, Theramex, Versanis Bio and Chugai; (2) has been a member of the Speakers Bureau for IBSA, RADIUS HEALTH, VIATRIS, AGNOVOS and TRB CHEMEDICA; (3) has received research grants (through institutions) from IBSA, Radius Health, Echolight, Viatris, Theramex and TRB Chemedica. Jean-Yves Reginster is an Editorial Board member of Drugs. Professor Reginster was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As a systematic literature review, ethical approval was not required to conduct this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All relevant data that support the findings of this study have been reported in the manuscript and in the supplementary information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"G.H., O.B. and J.Y.R. conceived the study and design. G.H. and O.B. drafted the review protocol. G.H. conducted the literature search. G.H. and L.L. contributed to the study selection, data extraction and risk of bias assessment. G.H., O.B., L.L., J.Y.R., M.A. and N.A.-D. contributed to the interpretation of the data. G.H. and O.B. drafted the manuscript. All authors critically reviewed the manuscript and gave their approval for this version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}